DiaMedica Therapeutics (DMAC) Capital Leases (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Capital Leases for 9 consecutive years, with $1000.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases fell 90.0% year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at $1000.0 (down 90.0% YoY), and the FY2025 full-year result was $4000.0, down 66.67% from the prior year.
• Capital Leases fell to $1000.0 in Q1 2026 per DMAC's latest filing, from $4000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $377000.0 in Q1 2023 and bottomed at $1000.0 in Q4 2023.
• Historically, Capital Leases has averaged $52187.5 across 5 years, with a median of $7500.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Capital Leases jumped 5000.0% in 2023, then plunged 95.52% in 2024.
• Over 5 years, Capital Leases stood at $4000.0 in 2022, then plunged by 75.0% to $1000.0 in 2023, then surged by 1100.0% to $12000.0 in 2024, then plunged by 66.67% to $4000.0 in 2025, then plunged by 75.0% to $1000.0 in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $1000.0, $4000.0, and $7000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.